Application No.: 10/583,977 Docket No.: 677132000200

CLAIM AMENDMENTS

1-20. (canceled)

- 21. (currently amended): A method to desensitize a subject to an allergic reaction to 2S albumin which method comprises administering to said subject a 2S albumin which has been modified by reducing essentially all of the disulfide bonds thereof and alkylating the resultants.
- 22. (previously presented): The method of claim 21 wherein the 2S albumin is Brazil nut 2S albumin.
- 23. (new): The method of claim 21 wherein said reducing has been performed using a reducing agent selected from the group consisting of 2-mercaptoethanol, dithiothreitol, dithioerythritol, and tributylphosphine, and combinations thereof.
- 24. (new): The method of claim 21 wherein said alkylating employs an alkylating agent selected from the group consisting of N-ethylmaleimide, cystamine, iodoacetamide, and iodoacetic acid, and combinations thereof.
- 25. (new): The method of claim 21 wherein said administering is oral or parenteral and said desensitizing results in reduction of any IgE response to zero.
- 26. (new): A method to desensitize a subject to an allergic reaction to a subsequently administered 2S albumin which method comprises previously administering to said subject a modified form of said 2S albumin which has been modified by reducing essentially all of the disulfide bonds thereof and alkylating the resultants.
 - 27. (new): The method of claim 26 wherein the 2S albumin is Brazil nut 2S albumin.

sd-575105 2

Application No.: 10/583,977 Docket No.: 677132000200

28. (new): The method of claim 26 wherein said reducing has been performed using a reducing agent selected from the group consisting of 2-mercaptoethanol, dithiothreitol, dithioerythritol, and tributylphosphine, and combinations thereof.

- 29. (new): The method of claim 26 wherein said alkylating has employed an alkylating agent selected from the group consisting of N-ethylmaleimide, cystamine, iodoacetamide, and iodoacetic acid, and combinations thereof.
- 30. (new): The method of claim 26 wherein said administering is oral or parenteral and said desensitizing results in reduction of any IgE response to zero.

sd-575105 3